AU2022227585A1 - Dynamic bioactive scaffolds and therapeutic uses thereof after cns injury - Google Patents

Dynamic bioactive scaffolds and therapeutic uses thereof after cns injury Download PDF

Info

Publication number
AU2022227585A1
AU2022227585A1 AU2022227585A AU2022227585A AU2022227585A1 AU 2022227585 A1 AU2022227585 A1 AU 2022227585A1 AU 2022227585 A AU2022227585 A AU 2022227585A AU 2022227585 A AU2022227585 A AU 2022227585A AU 2022227585 A1 AU2022227585 A1 AU 2022227585A1
Authority
AU
Australia
Prior art keywords
peptide
ikvav
segment
mimetic
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022227585A
Other languages
English (en)
Inventor
Zaida Alvarez Pinto
Samuel Isaac STUPP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of AU2022227585A1 publication Critical patent/AU2022227585A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022227585A 2021-02-23 2022-02-23 Dynamic bioactive scaffolds and therapeutic uses thereof after cns injury Pending AU2022227585A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152498P 2021-02-23 2021-02-23
US63/152,498 2021-02-23
PCT/US2022/017490 WO2022182737A2 (en) 2021-02-23 2022-02-23 Dynamic bioactive scaffolds and therapeutic uses thereof after cns injury

Publications (1)

Publication Number Publication Date
AU2022227585A1 true AU2022227585A1 (en) 2023-09-14

Family

ID=83048442

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022227585A Pending AU2022227585A1 (en) 2021-02-23 2022-02-23 Dynamic bioactive scaffolds and therapeutic uses thereof after cns injury

Country Status (9)

Country Link
US (1) US20240325548A1 (https=)
EP (1) EP4298111A4 (https=)
JP (1) JP2024507871A (https=)
KR (1) KR20230148425A (https=)
AU (1) AU2022227585A1 (https=)
CA (1) CA3209358A1 (https=)
IL (1) IL305375A (https=)
MX (1) MX2023009786A (https=)
WO (1) WO2022182737A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118072851A (zh) * 2024-04-24 2024-05-24 中国科学院苏州纳米技术与纳米仿生研究所 一种基于粗粒化分子动力学模拟的自组装肽结构预测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070749A2 (en) * 2002-02-15 2003-08-28 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7544661B2 (en) * 2003-12-05 2009-06-09 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
US7671012B2 (en) * 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
WO2006014530A2 (en) * 2004-07-07 2006-02-09 The General Hospital Corporation Imaging of enzyme activity
AU2006206194A1 (en) * 2005-01-21 2006-07-27 Northwestern University Methods and compositions for encapsulation of cells
WO2006096614A2 (en) * 2005-03-04 2006-09-14 Northwestern University Angiogenic heparin binding peptide amphiphiles
US9457064B2 (en) * 2005-07-29 2016-10-04 Abburi Ramaiah Method for treatment of vitiligo
AU2006290251B2 (en) * 2005-09-13 2011-12-08 Abburi Ramaiah Agonist peptides of basic fibroblast growth factor (BFGF) and the method of reduction of wrinkle on skin, darkening of hair and acceleration of wound healing
WO2008039483A2 (en) * 2006-09-26 2008-04-03 Massachusetts Institute Of Technology Modified self-assembling peptides
US8772228B2 (en) * 2007-02-14 2014-07-08 Northwestern University Aligned nanofibers and related methods of use
EP2310035B1 (en) * 2008-06-16 2015-08-26 University Of Rochester Fibroblast growth factor (fgf) analogs and uses thereof
US20170021056A1 (en) * 2015-07-20 2017-01-26 Northwestern University Peptide amphiphile biomaterials for nerve repair
WO2019195741A1 (en) * 2018-04-06 2019-10-10 Northwestern University Bdnf mimetic peptide amphiphiles
WO2020097460A1 (en) * 2018-11-09 2020-05-14 Northwestern University Self-assembling vegf nanoparticles
WO2020154631A1 (en) * 2019-01-24 2020-07-30 Northwestern University Dynamics within supramolecular 1kvav matrices enhance functional maturation of human ipscs-der1ved neurons and regeneration

Also Published As

Publication number Publication date
EP4298111A4 (en) 2025-01-15
KR20230148425A (ko) 2023-10-24
JP2024507871A (ja) 2024-02-21
WO2022182737A3 (en) 2022-12-15
CA3209358A1 (en) 2022-09-01
US20240325548A1 (en) 2024-10-03
MX2023009786A (es) 2023-10-09
IL305375A (en) 2023-10-01
WO2022182737A2 (en) 2022-09-01
EP4298111A2 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
Hosseinkhani et al. Enhanced angiogenesis through controlled release of basic fibroblast growth factor from peptide amphiphile for tissue regeneration
Cheng et al. Neural stem cells encapsulated in a functionalized self-assembling peptide hydrogel for brain tissue engineering
Sur et al. A hybrid nanofiber matrix to control the survival and maturation of brain neurons
CN101472944B (zh) 用于诱导细胞外基质蛋白合成的肽片段
JP7560884B2 (ja) 超分子ｉｋｖａｖマトリックス内の動力学は、ヒトｉｐｓｃ由来のニューロンの機能的成熟と再生を増強する
WO2012149515A2 (en) Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
Kulkarni et al. Esterase-mediated sustained release of peptide-based therapeutics from a self-assembled injectable hydrogel
US20240325548A1 (en) Dynamic bioactive scaffolds and therapeutic uses thereof after cns injury
US20220056219A1 (en) Host-guest interactions for pa superstructure formation
JP2024507871A5 (https=)
US12122811B2 (en) BDNF mimetic peptide amphiphiles
US11998589B2 (en) PEGylated peptide amphiphile nanofibers and methods of use
US20260092252A1 (en) Netrin-1 mimetic peptide amphiphiles
US20260035413A1 (en) Sliding bioactive peptides for therapeutic delivery
US12247063B2 (en) Cell surface modification by coating with peptide amphiphiles (PAs)
US20250154455A1 (en) Bioactive and antioxidant supramolecular polymer hydrogels for neural cell culture
US12570709B2 (en) Self-assembling peptide amphiphiles displaying a transforming growth factor beta 1 (TGF-ß1) mimetic epitope
US20220118051A1 (en) Self-assembling vegf nanoparticles
Smith Supramolecular Peptide Amphiphile Nanostructures for Central Nervous System Regeneration
EP4317190A1 (en) C-met protein-binding peptide complex
Kolberg-Edelbrock Development of Bioactive Peptide Amphiphile Injectable Hydrogels for Regeneration of the Central Nervous System
US20100035820A1 (en) Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation
Khan Incorporating Specific Biological Functionality into Self-Assembling Peptide Amphiphiles for Nanostructured Biomaterials